

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. **(Previously presented)** An oligopeptide having the amino acid sequence:
Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO:13).
2. **(Previously presented)** The oligopeptide according to Claim 1 wherein one or more of the amino acids of said oligopeptide are D isomers.
3. **(Previously presented)** The oligopeptide according to Claim 2, wherein all the amino acids of said oligopeptide, other than glycine, are D isomers.
4. **(Currently amended)** The oligopeptide according to ~~any one of Claims 1 to 3~~ Claim 1, wherein the terminal carboxyl group of said oligopeptide is amidated.
5. **(New)** The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is amidated.
6. **(New)** The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is amidated.
5. 7. **(Currently amended)** The oligopeptide according to ~~any one of Claims 1 to 4~~ Claim 1, wherein said oligopeptide is in salt form.
8. **(New)** The oligopeptide according to Claim 2, wherein said oligopeptide is in salt form.
9. **(New)** The oligopeptide according to Claim 3, wherein said oligopeptide is in salt form.
10. **(New)** The oligopeptide according to Claim 4, wherein said oligopeptide is in salt form.
11. **(New)** The oligopeptide according to Claim 5, wherein said oligopeptide is in salt form.

12. (New) The oligopeptide according to Claim 6, wherein said oligopeptide is in salt form.

6- 13. (Currently amended) The oligopeptide according to ~~Claim 5~~ Claim 1, wherein said ~~the~~ terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

14. (New) The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

15. (New) The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

16. (New) The oligopeptide according to Claim 4, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

17. (New) The oligopeptide according to Claim 5, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

18. (New) The oligopeptide according to Claim 6, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

19. (New) The oligopeptide according to Claim 7, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

20. (New) The oligopeptide according to Claim 8, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.


21. (New) The oligopeptide according to Claim 9, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

22. (New) The oligopeptide according to Claim 10, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

23. (New) The oligopeptide according to Claim 11, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

24. (New) The oligopeptide according to Claim 12, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

~~7.~~ 25. (Currently amended) An oligopeptide having the structural formula:



~~8.~~ 26. (Currently amended) A pharmaceutical composition comprising an oligopeptide according to any one of ~~Claims 1 to 7~~ Claims 1-25 and a pharmaceutically acceptable medium.

~~9.~~ 27. (Currently amended) The pharmaceutical composition according to ~~Claim 8~~ Claim 26, wherein said pharmaceutically acceptable medium comprises an excipient.

~~10.~~ 28. (Currently amended) The pharmaceutical composition according to ~~Claim 9~~ Claim 27, wherein said excipient comprises mannitol.